首页> 外文期刊>Molecular cancer research: MCR >Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition
【24h】

Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition

机译:Olaparib诱导的适应性反应被Foxm1靶向置于增强对PARP抑制的敏感性

获取原文
获取原文并翻译 | 示例
           

摘要

FOXM1 transcription factor network is activated in over 84% of cases in high-grade serous ovarian cancer (HGSOC), and FOXM1 upregulates the expression of genes involved in the homologous recombination (HR) DNA damage and repair (DDR) pathway. However, the role of FOXM1 in PARP inhibitor response has not yet been studied. This study demonstrates that PARP inhibitor (PARPi), olaparib, induces the expression and nuclear localization of FOXM1. On the basis of ChI-PqPCR, olaparib enhances the binding of FOXM1 to genes involved in HR repair. FOXM1 knockdown by RNAi or inhibition by thiostrepton decreases FOXM1 expression, decreases the expression of HR repair genes, such as BRCA1 and RAD51, and enhances sensitivity to olaparib. Comet and PARP trapping assays revealed increases in DNA damage and PARP trapping in FOXM1-inhibited cells treated with olaparib. Finally, thiostrepton decreases the expression of BRCA1 in rucaparib-resistant cells and enhances sensitivity to rucaparib. Collectively, these results identify that FOXM1 plays an important role in the adaptive response induced by olaparib and FOXM1 inhibition by thiostrepton induces "BRCAness" and enhances sensitivity to PARP inhibitors. (C) 2018 AACR.
机译:FOXM1转录因子网络在高级浆液癌癌(HGSOC)的84%案例中被激活,并且FOXM1上调了涉及同源重组(HR)DNA损伤和修复(DDR)途径的基因的表达。然而,尚未研究FoxM1在PARP抑制剂反应中的作用。本研究表明,PARP抑制剂(PARPI),奥拉帕里布诱导FOXM1的表达和核定位。在CHI-PQPCR的基础上,奥拉帕里布增强FOXM1对HR修复中涉及的基因的结合。通过RNAi敲低的Foxm1通过Thiostrepton抑制降低FoxM1表达,降低了HR修复基因,例如BRCA1和RAD51的表达,并增强了对Olaparib的敏感性。 COMET和PARP捕获测定显示DNA损伤的增加和用奥拉帕布处理的FOXM1抑制细胞中的PARP捕获。最后,Thiostrepton降低了抗Rucaparib抗细胞中BRCA1的表达,并提高了对Rucaparib的敏感性。总的来说,这些结果鉴定了Foxm1在奥拉帕里布和硫氧化物诱导的“Brcaness”诱导的ops诱导的适应性反应中起重要作用,并增强对PARP抑制剂的敏感性。 (c)2018年AACR。

著录项

  • 来源
    《Molecular cancer research: MCR》 |2018年第6期|共13页
  • 作者单位

    Univ Kansas Med Ctr Dept Pharmacol Toxicol &

    Therapeut Kansas City KS 66103 USA;

    Univ Kansas Med Ctr Dept Canc Biol Kansas City KS 66103 USA;

    Univ Kansas Med Ctr Dept Canc Biol Kansas City KS 66103 USA;

    Univ Kansas Sch Pharm Dept Pharmaceut Chem Lawrence KS 66045 USA;

    Univ Kansas Sch Pharm Dept Pharmaceut Chem Lawrence KS 66045 USA;

    Univ New Mexico Sch Med Comprehens Canc Ctr Dept Internal Med Albuquerque NM 87131 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号